LexaGene completes C$5.75 Million Bought Deal Financing. Underwriters Exercise Over-Allotment Option in Full.
18 June 2018
LexaGene names medical device veteran Joseph Caruso to Board of Directors. Mr. Caruso was responsible for the successful worldwide commercial launch of dozens of medical devices over his 30-year career.
06 June 2018
LexaGene announces a collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory to begin testing canine dog urine samples on LexaGene’s LX6 prototype.
29 May 2018
LexaGene has entered into an agreement with the Stanford University School of Medicine to incorporate cancer sequencing technology into a new product.
15 May 2018
LexaGene announces that its prototype for more effective pathogen detection is now generating data, and is capable of identifying E. coli and Staph.
04 April 2018
LexaGene has entered into a collaboration with Ethos Veterinary Health to begin testing canine dog urine samples on LexaGene’s LX6 prototype.